Heights key facts
- Producer of smart supplements intended to elevate and extend cognitive performance by nourishing the brain.
- Heights’s last known valuation is $46.5M.
- It has raised $16.5M; the latest was Equity Crowdfunding ($2.7M) in Oct 2024.
- Notable investors include Innovate UK, Spacestation (UK), EGR Partners, Turquoise International, Alex Heineken — 21 tracked in total.
- Status: Privately Held (backing).
Who backs Heights
21+- ·The complete investor list: 21 names
- ·Watch Heights: the Monday email on marks, rounds and moves
Heights funding rounds
No funding rounds for Heights are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Heights valuation
Heights's last known valuation is $46.5 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Heights investors
21 investors are on record for Heights, including Innovate UK, Spacestation (UK), EGR Partners and Turquoise International.
About Heights
Producer of smart supplements intended to elevate and extend cognitive performance by nourishing the brain. The company's supplements focus on giving the brain the fuel it needs to improve its health performance and mental well-being, enabling customers to get the nourishment they require according to neuroscience and optimize human potential.
- Sector
- Consumer Products and Services (B2C)
- HQ
- London, United Kingdom
- Founded
- 2013
- Employees
- 94
- Website
- heights.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Heights’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.